Original ArticleTranslating plasma eicosapentaenoic acid concentrations into erythrocyte percentages of eicosapentaenoic acid plus docosahexaenoic acid during treatment with icosapent ethyl

Add time:08/25/2019    Source:sciencedirect.com

BackgroundThe Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (REDUCE-IT) study demonstrated that 4 g/d of eicosapentaenoic acid (EPA) ethyl esters (icosapent ethyl [IPE]) reduced risk for major cardiovascular events by 25% in statin-treated patients with residual hypertriglyceridemia. How this treatment affected red blood cell (RBC) EPA and docosahexaenoic acid (DHA) levels (ie, the Omega-3 Index [O3I]) was not reported, but effects on plasma EPA concentrations were reported.

We also recommend Trading Suppliers and Manufacturers of (S)-3-CYANO-3-HYDROXY-PROPIONIC ACID ETHYL ESTER (cas 132839-91-9). Pls Click Website Link as below: cas 132839-91-9 suppliers

Prev:Poly(arylene ether)s with trifluoromethyl groups via meta-activated nitro displacement reaction
Next:FT-IR extra virgin olive oil classification based on ethyl ester content)